Anticipatory and consummatory effects of (hedonic) chocolate intake are associated with increased circulating levels of the orexigenic peptide ghrelin and endocannabinoids in obese adults

Food and Nutrition Research

Volumn 59, Issue , 2015, Pages

  Rigamonti, Antonello E ^a   Piscitelli, Fabiana ^b   Aveta, Teresa ^b   Agosti, Fiorenza ^c   De Col, Alessandra ^c   Bini, Silvia ^a   Cella, Silvano G ^a   Di Marzo, Vincenzo ^b   Sartorio, Alessandro ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Endocannabinoids; Ghrelin; GLP 1; Hunger; Obesity; Palatable food; PYY; Satiety

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ENDOCANNABINOID; GHRELIN; GLUCAGON LIKE PEPTIDE 1; N OLEOYLETHANOLAMINE; PALMIDROL; PEPTIDE YY;

ADULT; ANTICIPATION; ARTICLE; BODY MASS; CACAO; CALORIC INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FAT FREE MASS; FAT MASS; FOOD INTAKE; HEDONIC HUNGER; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HUNGER; MALE; MOTIVATION; OBESITY; PALATABILITY; PLEASURE; SATIETY; VISUAL ANALOG SCALE;

EID: 84958280838     PISSN: 16546628     EISSN: None     Source Type: Journal    
DOI: 10.3402/fnr.v59.29678     Document Type: Article

References (38)

1. Egecioglu E, Skibicka KP, Hansson C, Alvarez-Crespo M, Friberg PA, Jerlhag E, et al. Hedonic and incentive signals for body weight control. Rev EndocrMetab Disord 2011; 12: 141-51.
2. Yeomans MR, Blundell JE, Leshem M. Palatability: response to nutritional need or need-free stimulation of appetite? Br J Nutr 2004; 92: S3-14.
3. Zheng H, Berthoud HR. Neural systems controlling the drive to eat: mind versus metabolism. Physiology 2008; 23: 75-83.
4. Finlayson G, King N, Blundell JE. Liking vs. wanting food: importance for human appetite control and weight regulation. Neurosci Biobehav Rev 2007; 31: 987-1002.
5. Lutter M, Nestler EJ. Homeostatic and hedonic signals interact in the regulation of food intake. J Nutr 2009; 139: 629-32.
6. Rui L. Brain regulation of energy balance and body weight. Rev Endocr Metab Disord 2013; 14: 387-407.
7. Jerlhag E, Egecioglu E, Dickson SL, Douhan A, Svensson L, Engel JA. Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens. Addict Biol 2007; 12: 6-16.
8. Dickson SL, Egecioglu E, Landgren S, Skibicka KP, Engel JA, Jerlhag E. The role of the central ghrelin system in reward from food and chemical drugs. Mol Cell Endocrinol 2011; 340: 80-7.
9. Di Marzo V, Ligresti A, Cristino L. The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Int J Obes 2009; 33: S18-24.
10. Cristino L, Becker T, Di Marzo V. Endocannabinoids and energy homeostasis: an update. Biofactors 2014; 40: 389-97.
11. Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 2005; 30: 1216-21.
12. Monteleone P, Piscitelli F, Scognamiglio P, Monteleone AM, Canestrelli B, Di Marzo V, et al. Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. J Clin Endocrinol Metab 2012; 97: E917-24.
13. di Tomaso E, Beltramo M, Piomelli D. Brain cannabinoids in chocolate. Nature 1996; 382: 677-8.
14. Di Marzo V, Sepe N, De Petrocellis L, Berger A, Crozier G, Fride E, et al. Trick or treat from food endocannabinoids? Nature 1998; 396: 636-7.
15. Garner DM, Olmsted MP, Bohr Y, Garfinkel PE. The eating attitudes test: psychometric features and clinical correlates. Psychol Med 1982; 12: 871-8.
16. Annuzzi G, Piscitelli F, Di Marino L, Patti L, Giacco R, Costabile G, et al. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis 2010; 9: 43.
17. TschöpM,Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-9.
18. English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 2002; 87: 2984.
19. Simonian HP, Kresge KM, Boden GH, Parkman HP. Differential effects of sham feeding and meal ingestion on ghrelin and pancreatic polypeptide levels: evidence for vagal efferent stimulation mediating ghrelin release. Neurogastroenterol Motil 2005; 17: 348-54.
20. Malik S, McGlone F, Bedrossian D, Dagher A. Ghrelin modulates brain activity in areas that control appetitive behaviour. Cell Metab 2008; 7: 400-9.
21. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev 1998; 28: 309-69.
22. Karra E, O'Daly OG, Choudhury AI, Yousseif A, Millership S, Neary MT, et al. A link between FTO, ghrelin, and impaired brain food-cue responsivity. J Clin Invest 2013; 123: 3539-51.
23. De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA, et al. The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 2011; 14: 700-6.
24. Batterham RL, Cohen MA, Ellis SM, Le Roux CW,Withers DJ, Frost GS, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941-8.
25. Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999; 23: 304-11.
26. Horvath TL, Castañeda T, Tang-Christensen M, Pagotto U, Tschöp MH. Ghrelin as a potential anti-obesity target. Curr Pharm Des 2003; 9: 1383-95.
27. Álvarez-Castro P, Pena L, Cordido F. Ghrelin in obesity, physiological and pharmacological considerations. Mini Rev Med Chem 2013; 13: 541-52.
28. Jager G, Witkamp RF. The endocannabinoid system and appetite: relevance for food reward. Nutr Res Rev 2014; 27: 172-85.
29. Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, Borrelli F, et al. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol 2009; 158: 451-61.
30. Di Patrizio NV, Astarita G, Schwartz G, Li X, Piomelli D. Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci USA 2011; 108: 12904-8.
31. Di Marzo V. Endocannabinoids: an appetite for fat. Proc Natl Acad Sci USA 2011; 108: 12567-8.
32. Kola B, Farkas I, Christ-Crain M, Wittmann G, Lolli F, Amin F, et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One 2008; 3: e1797.
33. Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr 2004; 92: 757-61.
34. Rigamonti AE, Giordani C, Bonomo SM, Cella SG,üller EE. Early tolerance to the hypophagic effect of the cannabinoid receptor antagonist SR141716 does not impede blockade of an orexigenic stimulus. Eur J Pharmacol 2006; 542: 116-20.
35. Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, et al. Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry 2011; 69: 633-41.
36. Di Marzo V, Verrijken A, Hakkarainen A, Petrosino S, Mertens I, Lundbom N, et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 2009; 161: 715-22.
37. Valenti M, Viganò D, Casico MG, Rubino T, Steardo L, Parolaro D, et al. Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cell Mol Life Sci 2004; 61: 945-50.
38. Osman JL, Sobal J. Chocolate cravings in American and Spanish individuals: biological and cultural influences. Appetite 2006; 47: 290-301.